-
Founded in:
2003-08-15 -
Country:
China -
Address:
No. 51, Qianyang East Road, Taifeng Office, Qianjiang City -
Tax NO.:
9142900575104555XW -
Registered Funds:
10 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Thrombin |
It promotes the conversion of fibrinogen into fibrin, which is applied to wounds to coagulate blood and stop bleeding.
More
It promotes the conversion of fibrinogen into fibrin, which is applied to wounds to coagulate blood and stop bleeding. |
More than 80% of the labeled amountUnit/mg | 9002-04-4 | 3 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Bifonazole |
This product is an imidazole antifungal drug with a broad spectrum of anti-dermatophytes, yeasts, filamentous fungi and dimorphic fungi, and has strong antibacterial activity. It is also effective against Malassezia furfur and Gram-positive cocci. This drug has a good effect on experimental dermatophytosis in animals. Like other imidazole drugs, this product has an inhibitory effect on C14-demethylation, preventing it from forming ergosterol, and can also reduce the production of mevalonic acid so that it cannot form squalene, thereby affecting the synthesis of fungal ergosterol.
More
This product is an imidazole antifungal drug with a broad spectrum of anti-dermatophytes, yeasts, filamentous fungi and dimorphic fungi, and has strong antibacterial activity. It is also effective against Malassezia furfur and Gram-positive cocci. This drug has a good effect on experimental dermatophytosis in animals. Like other imidazole drugs, this product has an inhibitory effect on C14-demethylation, preventing it from forming ergosterol, and can also reduce the production of mevalonic acid so that it cannot form squalene, thereby affecting the synthesis of fungal ergosterol. |
60628-96-8 | 11 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ursodeoxycholic acid |
By inhibiting the reabsorption of cholesterol in the intestine and reducing the secretion of cholesterol into the bile, the saturation of cholesterol in the bile is reduced. Cholesterol stones may be gradually dissolved due to the dispersion of cholesterol and the formation of liquid crystals. The treatment of liver and cholestatic diseases is mainly based on the relative replacement of lipophilic, detergent-like toxic bile acids by hydrophilic, cytoprotective and non-cytotoxic ursodeoxycholic acid, as well as the promotion of hepatocyte secretion and immunomodulation.
More
By inhibiting the reabsorption of cholesterol in the intestine and reducing the secretion of cholesterol into the bile, the saturation of cholesterol in the bile is reduced. Cholesterol stones may be gradually dissolved due to the dispersion of cholesterol and the formation of liquid crystals. The treatment of liver and cholestatic diseases is mainly based on the relative replacement of lipophilic, detergent-like toxic bile acids by hydrophilic, cytoprotective and non-cytotoxic ursodeoxycholic acid, as well as the promotion of hepatocyte secretion and immunomodulation. |
128-13-2 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Azithromycin |
Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. It mainly binds to the 50S subunit of the bacterial ribosome and inhibits RNA-dependent protein synthesis.
More
Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. It mainly binds to the 50S subunit of the bacterial ribosome and inhibits RNA-dependent protein synthesis. |
83905-01-5 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Lansoprazole |
(1) It is an antacid and anti-ulcer drug. (2) It is a new type of proton pump inhibitor. After oral absorption, it enters the gastric parietal cells from the blood and is converted into a sulfonamide derivative that can bind to H-K-ATPase in the strong acidic environment of the gastric parietal cells, inactivating the enzyme and inhibiting central and peripheral regulated gastric acid secretion. It can also reduce the secretion of pepsin, reduce its activity, and eliminate Helicobacter pylori in the gastric mucosa.
More
(1) It is an antacid and anti-ulcer drug. (2) It is a new type of proton pump inhibitor. After oral absorption, it enters the gastric parietal cells from the blood and is converted into a sulfonamide derivative that can bind to H-K-ATPase in the strong acidic environment of the gastric parietal cells, inactivating the enzyme and inhibiting central and peripheral regulated gastric acid secretion. It can also reduce the secretion of pepsin, reduce its activity, and eliminate Helicobacter pylori in the gastric mucosa. |
103577-45-3 | 88 |